Browse the evidence

Orlistat provides modest weight loss and cardiovascular risk reduction, but its efficacy is heavily dependent on dietary fat restriction.

Orlistat is an older weight loss medication that works by blocking fat absorption. It is less effective than newer drugs and requires you to eat a low-fat diet to avoid unpleasant gastrointestinal side effects like oily diarrhea. It may offer some cardiovascular benefits for people with metabolic syndrome.

Phentermine/topiramate combination therapy results in significant weight loss but is associated with increased heart rate and potential psychiatric side effects.

Phentermine/topiramate is a combination pill that can lead to significant weight loss. However, it can increase your heart rate and cause psychiatric side effects like anxiety or depression. It requires careful monitoring by a doctor, and if you don't lose enough weight after a few months, the treatment may be stopped.

Bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion, induces Type 2 Diabetes remission in a majority of patients through mechanisms exceeding simple caloric restriction, including hormonal changes (GLP-1, PYY) and altered gut microbiome.

For eligible patients with obesity and T2DM, bariatric surgery is the most potent intervention for achieving remission, often outperforming medication. It works by altering gut hormones that improve insulin sensitivity, not just by making the stomach smaller. Consultation with a bariatric specialist is required to assess eligibility based on BMI and diabetes duration.

Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.

Newer medications like Tirzepatide (a dual agonist) may offer greater weight loss and improvements in blood pressure and cholesterol than older GLP-1 drugs. However, long-term data on whether this translates to fewer heart attacks or strokes is still being collected. If standard GLP-1s are not achieving your metabolic goals, discuss these newer options with your doctor.

In overweight or obese diabetic patients, higher initial BMI (specifically >35 kg/m2 and >40 kg/m2) is associated with a dose-dependent increase in all-cause mortality.

If your BMI is above 35 or 40, your risk of death from any cause is higher than those with a BMI of 25-30. While the 'obesity paradox' exists, it does not protect against the risks of extreme obesity. Focus on managing diabetes and cardiovascular health rather than just weight.

Women exhibit a significantly greater relative increase in maximal strength (1RM Bench Press) compared to men after 16 weeks of resistance training, although absolute strength gains may be larger in men.

If you are a woman, expect your relative strength gains (percentage increase) to be higher than men's on upper body pushing movements like the bench press. This may be due to neural adaptations or less prior familiarity with the exercise. Men may still lift more absolute weight, but women often see bigger percentage jumps.

Sustained high levels of physical activity expenditure trigger compensatory metabolic adaptations that decrease resting metabolic rate (RMR), thereby constraining total energy expenditure and facilitating long-term weight loss maintenance.

If you are maintaining significant weight loss through high levels of exercise, expect your resting metabolism to drop as a compensatory mechanism. This is not a sign that your exercise is ineffective; rather, it is a physiological adaptation that helps you keep the weight off. Do not interpret a plateau in weight loss despite high activity as a failure of your regimen, but as evidence of metabolic adaptation constraining total energy expenditure.

Low-calorie sweeteners do not negatively affect post-prandial glucose or insulin levels in healthy individuals or those with diabetes.

If you have diabetes or are concerned about blood sugar spikes, LCS are a safe alternative to sugar. They do not raise blood glucose or insulin levels, making them suitable for managing diabetes while still enjoying sweet tastes.

Low-calorie sweeteners are non-cariogenic and do not cause tooth decay, offering dental benefits when used in foods and beverages.

You can enjoy LCS in your food and drinks without worrying about cavities. They do not feed the bacteria that cause tooth decay, unlike sugar.

Lifestyle modification, specifically caloric restriction and specific diets (e.g., Mediterranean, low-carbohydrate), reduces body weight and improves insulin resistance and hepatic steatosis, but its efficacy is moderate and less sustainable than GLP-1RA.

Losing just 5% of your body weight through caloric restriction can significantly improve insulin sensitivity and reduce liver fat by up to 40%. While lifestyle changes are the foundation of treatment, they often result in moderate weight loss compared to medications like GLP-1RA. Combining caloric reduction with exercise is effective, but maintaining this long-term is challenging, which is why pharmacological support is often needed for significant, sustained results.

GLP-1 receptor agonists improve hepatic steatosis and MASH resolution primarily through weight loss and direct inhibition of hepatic de novo lipogenesis.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, achieving resolution in a significant portion of patients. They work by reducing liver fat through both weight loss and direct metabolic effects. Expect potential gastrointestinal side effects, which are usually manageable.

In real-world clinical practice, semaglutide produces attenuated weight loss (average 4.44%) compared to clinical trials, with diabetes mellitus diagnosis significantly reducing efficacy while linaclotide use and prediabetes are associated with enhanced weight loss.

If you are taking semaglutide in a standard clinical setting, expect an average weight loss of around 4-5% over a year, which is less than the 10-15% often cited from clinical trials. This difference is largely due to the lack of intensive lifestyle counseling provided in routine care. If you have diabetes, your weight loss may be further reduced, whereas having prediabetes or taking linaclotide might actually help you lose more weight.

Concomitant use of linaclotide is associated with significantly greater weight loss in patients taking semaglutide, whereas diabetes mellitus and dulaglutide use are associated with reduced efficacy.

If you are taking semaglutide, your other medications matter. Taking linaclotide (for constipation/IBS) is associated with better weight loss results, while taking diabetes medications like dulaglutide or metformin, or having a diabetes diagnosis, is associated with less weight loss. This suggests that your specific health profile and other drugs significantly influence semaglutide's effectiveness.

Canagliflozin treatment in patients with type 2 diabetes mellitus reduces cardiovascular risk factors by inducing mild osmotic diuresis, natriuresis, and weight loss, leading to significant reductions in blood pressure and body weight.

For patients with Type 2 Diabetes and high cardiovascular risk, canagliflozin (100-300 mg daily) offers benefits beyond blood sugar control, specifically lowering blood pressure and body weight through fluid loss and caloric excretion. This multifactorial risk reduction is recommended by guidelines for patients with existing cardiovascular disease, provided their kidney function (eGFR) is above 45 mL/min/1.73 m2.

Binge eating behaviors reduce the efficacy of weight loss interventions in type 2 diabetes, and dieting itself can be a risk factor for the onset of binge eating.

Be aware that restrictive dieting can trigger binge eating in some patients with type 2 diabetes. If binge eating is present, it will hinder weight loss success. Address this by avoiding punitive language and focusing on positive, varied food choices rather than strict restriction.

Anti-obesity medications (AOMs) including GLP-1 receptor agonists (liraglutide, semaglutide) and other agents (naltrexone-bupropion, phentermine-topiramate, orlistat) are significantly underutilized in clinical practice, with only 8% of eligible patients receiving a prescription and 4.4% filling it.

If you have obesity (BMI ≥30) and are interested in anti-obesity medications (AOMs) like GLP-1 agonists (e.g., semaglutide, liraglutide), be aware that access is heavily restricted by insurance type and demographics. In this study, only 8% of eligible patients got a prescription, and 4.4% filled it. If you are insured by Medicaid, Medicare, or are a minority, you face significantly lower odds of receiving these medications. Discuss these barriers with your provider and advocate for coverage options, as private insurance offers better access than public programs.

Oral semaglutide at 50 mg once daily achieves significantly greater HbA1c reduction (2.1%) and weight loss (9.8%) compared to the approved 14 mg dose, with higher discontinuation rates due to gastrointestinal adverse events.

If you have Type 2 Diabetes and struggle with blood sugar or weight, oral semaglutide 50mg is a potent non-injectable option. It works better than the standard 14mg dose, lowering HbA1c by 2.1% and causing nearly 10% weight loss. However, be prepared for potential stomach issues like nausea, which are common but usually mild. Take it on an empty stomach with a small sip of water as directed.

Short-term (10-day) time-restricted eating (8-hour window) does not impair daily myofibrillar protein synthesis rates compared to an extended 12-hour eating window when protein intake is matched.

If you are an overweight or obese male who exercises recreationally, switching to an 8-hour eating window (e.g., 10 AM to 6 PM) for 10 days will not hurt your muscle protein synthesis, provided you eat the same amount of protein (1g/kg) as you would over a longer period. Focus on hitting your daily protein goal rather than worrying about the clock.

Short-term time-restricted eating (8-hour window) improves 24-hour glucose homeostasis (reduced area under the curve) compared to an extended 12-hour eating window, despite identical food intake.

Compressing your eating window to 8 hours (e.g., 10 AM to 6 PM) can significantly improve your daily blood glucose control, even if you eat the exact same amount of food as you would over 12 hours. This is achieved by shifting meal times to delay breakfast and finish dinner earlier, which helps manage glucose spikes.

Supplementation with 15g/day of specific bioactive collagen peptides (CP) during 15 weeks of resistance training significantly increases skeletal muscle volume (hypertrophy) compared to placebo, without enhancing maximum strength gains.

If you are doing resistance training, taking 15g of specific collagen peptides daily may help you build more muscle mass than training alone, particularly in the quadriceps. However, do not expect this to make you stronger faster; your strength gains will likely be similar to those achieved with a placebo. Focus on the structural benefits for tissue health rather than immediate power output.

Processing and cooking methods that reduce antinutrients, denature proteins, and reduce food particle size improve dietary protein quality by increasing essential amino acid (EAA) digestibility and bioavailability.

Don't fear processing plant proteins. Cooking beans, lentils, and grains, or using protein isolates/powders, often makes the protein more digestible and bioavailable than eating them raw or in their whole, unprocessed form. This is especially important if you rely on plant-based proteins to meet your daily needs.

High fructose intake, particularly from sweet beverages, drives hepatic de novo lipogenesis and steatosis in NAFLD, independent of total caloric intake.

Eliminate sugar-sweetened beverages (soda, juice, sweet tea) and limit added fructose. This reduces liver fat production directly, even if your total calorie intake doesn't change. Focus on whole foods rather than processed sugars.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant, dose-dependent weight loss (8.5–8.8%) in adults with obesity at doses of 24–36 mg/day, with gastrointestinal side effects being the primary limiting factor.

Take orforglipron once daily. Start at a low dose (6-9 mg) and increase to 12 mg, then to 24-36 mg as tolerated. Expect 8-9% body weight loss over 6 months. Manage nausea by titrating slowly.

Dual agonists of GLP-1 and glucagon (GCGR) or GIP receptors provide greater weight loss and broader metabolic benefits than mono-agonists, potentially addressing treatment barriers like cost and access by treating non-cardiometabolic complications.

If you have obesity, especially with related conditions like diabetes or fatty liver, newer dual-agonist medications (like tirzepatide) may offer significantly greater weight loss and health benefits than older drugs. However, access is currently limited by cost and insurance coverage. Discuss these options with your doctor, focusing on how treating multiple complications might justify the expense.